BMJ3d
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs
The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental ...
BMJ2d
Single-cell transcriptomics reveal potent extrafollicular B cell response linked with granzyme K + CD8 T cell activation in lupus kidney
2 Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China 3 University of Chinese Academy of Sciences, Beijing, ...
BMJ5d
Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness
Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
BMJ6d
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ5d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
4 Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Universidade de Lisboa, and Centro Académico deMedicina de Lisboa, Lisbon, Portugal 5 Oxford NIHR Biomedical Research Centre ...
BMJ2d
Tumour-like mass lesion: an under-recognised presentation of primary angiitis of the central nervous system
Eamonn S Molloy, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; molloye{at}ccf.org Objective ...
BMJ4d
Studies with pain rating scales.
Good correlation has been shown between pain scores derived from 4 different rating scales. The correlation was maintained when presentation of the scales was separated by a series of questions and by ...
BMJ5d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ6d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ4d
Methotrexate: what are the true risks of treatment?
For more than three decades, low-dose methotrexate (MTX) has been the first-line treatment for patients with rheumatoid arthritis (RA). Even after the introduction of biologics/biosimilars and janus ...
BMJ4d
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or ...
BMJ4d
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
3 Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden 4 Department of Nephrology and Transplantation, Skane University Hospital Malmö, Lund University, Sweden Introduction ...